You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
An Interactive Informed Consent Program for Cardiac Procedures
SBC: ARCHIE MD INC. Topic: NHLBIDESCRIPTION (provided by applicant): Informed consent has become an essential component of the doctor-patient interaction. The informed consent process requires that patients not only be given information about proposed medical treatment, but that it be presented in an understandable way so the patient can make meaningful choices about medical alternatives. At the heart of the informed consent doc ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Internet-based Fidelity Enhancement of MTFC
SBC: Tfc Consultants, Inc. Topic: NIMHDESCRIPTION (provided by applicant): The proposed project builds upon Phase I proof of concept efforts wherein the basic foundational components of an Internet-based Treatment Fidelity Monitoring System, the ITFMS, were created to assist MTFC consultants and implementing agencies to improve clinical outcomes by moving more efficiently towards and maintaining fidelity of program implementation. I ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Development of Noninvasive System for Detection of Sleep Apnea in Animals
SBC: NEOGENE BIOSCIENCES, LLC Topic: NIADESCRIPTION (provided by applicant): The long term goal of this project is to develop and commercialize noninvasive equipment, called the sleep and respiratory track (SARTrak) system, for high throughput detection of sleep apnea in animals. The specific goal for the Phase I application is to design and evaluate a basic model of the SARTrak system with eight chambers (one chamber per animal), i.e. ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
A Synthetic Human Cytomegalovirus Vaccine Platform
SBC: TOMEGAVAX, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk
SBC: ZENAGENE, INC. Topic: NCIDESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Targeted Polymer Micelles for Treatment of Metastatic Melanoma
SBC: INTEZYNE TECHNOLOGIES, INC. Topic: NCIDESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors
SBC: SIXONE SOLUTIONS, LLC Topic: NCIDESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Live-Cell Fluorescence Lifetime FRET Assays for HTS
SBC: Fluorescence Innovations, Inc. Topic: NIDADESCRIPTION (provided by applicant): This project will establish proof-of-concept for a powerful and versatile implementation of live-cell assays in a true high-throughput screening (HTS) format for small-molecule drug discovery. The technological basis isfluorescence lifetime (FLT) readout of FRET between fluorescent fusion proteins. Lifetime measurement is needed in HTS to overcome the low preci ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Remote focusing through spatial light modulation for multifocal multiphoton micro
SBC: BOULDER NONLINEAR SYSTEMS, INC. Topic: NIMHDESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Neurorestorative therapy of stroke with HUCBC in T2DM rats
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health